Galanin-acetylcholine interactions: Relevance to memory and Alzheimer's disease

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

The neuropeptide, galanin, and its receptors are localized in the cholinergic basal forebrain and its projection areas in mammalian brain. Centrally administered galanin inhibits acetylcholine release in the rat ventral hippocampus, and produces deficits in learning and memory tasks. In Alzheimer's disease, galanin is overexpressed in terminals innervating the nucleus basalis of Meynert cell bodies. Selective galanin receptor antagonists provide a novel approach for increasing cholinergic function, as a potential adjunct to the clinical treatment of dementias.

Original languageEnglish (US)
Pages (from-to)2185-2199
Number of pages15
JournalLife Sciences
Volume58
Issue number24
DOIs
StatePublished - May 10 1996
Externally publishedYes

Fingerprint

Galanin Receptors
Galanin
Cholinergic Agents
Acetylcholine
Alzheimer Disease
Basal Nucleus of Meynert
Data storage equipment
Neuropeptides
Dementia
Rats
Hippocampus
Brain
Cells
Learning

Keywords

  • Acetylcholine
  • Alzheimer's disease
  • Galanin
  • Learning and memory
  • Neuropeptide
  • Neurotransmitter release

ASJC Scopus subject areas

  • Pharmacology

Cite this

Galanin-acetylcholine interactions : Relevance to memory and Alzheimer's disease. / Crawley, Jacqueline.

In: Life Sciences, Vol. 58, No. 24, 10.05.1996, p. 2185-2199.

Research output: Contribution to journalArticle

@article{e8a66d3b80af4cc3b60a253621a1ea09,
title = "Galanin-acetylcholine interactions: Relevance to memory and Alzheimer's disease",
abstract = "The neuropeptide, galanin, and its receptors are localized in the cholinergic basal forebrain and its projection areas in mammalian brain. Centrally administered galanin inhibits acetylcholine release in the rat ventral hippocampus, and produces deficits in learning and memory tasks. In Alzheimer's disease, galanin is overexpressed in terminals innervating the nucleus basalis of Meynert cell bodies. Selective galanin receptor antagonists provide a novel approach for increasing cholinergic function, as a potential adjunct to the clinical treatment of dementias.",
keywords = "Acetylcholine, Alzheimer's disease, Galanin, Learning and memory, Neuropeptide, Neurotransmitter release",
author = "Jacqueline Crawley",
year = "1996",
month = "5",
day = "10",
doi = "10.1016/0024-3205(96)00093-8",
language = "English (US)",
volume = "58",
pages = "2185--2199",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "24",

}

TY - JOUR

T1 - Galanin-acetylcholine interactions

T2 - Relevance to memory and Alzheimer's disease

AU - Crawley, Jacqueline

PY - 1996/5/10

Y1 - 1996/5/10

N2 - The neuropeptide, galanin, and its receptors are localized in the cholinergic basal forebrain and its projection areas in mammalian brain. Centrally administered galanin inhibits acetylcholine release in the rat ventral hippocampus, and produces deficits in learning and memory tasks. In Alzheimer's disease, galanin is overexpressed in terminals innervating the nucleus basalis of Meynert cell bodies. Selective galanin receptor antagonists provide a novel approach for increasing cholinergic function, as a potential adjunct to the clinical treatment of dementias.

AB - The neuropeptide, galanin, and its receptors are localized in the cholinergic basal forebrain and its projection areas in mammalian brain. Centrally administered galanin inhibits acetylcholine release in the rat ventral hippocampus, and produces deficits in learning and memory tasks. In Alzheimer's disease, galanin is overexpressed in terminals innervating the nucleus basalis of Meynert cell bodies. Selective galanin receptor antagonists provide a novel approach for increasing cholinergic function, as a potential adjunct to the clinical treatment of dementias.

KW - Acetylcholine

KW - Alzheimer's disease

KW - Galanin

KW - Learning and memory

KW - Neuropeptide

KW - Neurotransmitter release

UR - http://www.scopus.com/inward/record.url?scp=0029689910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029689910&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(96)00093-8

DO - 10.1016/0024-3205(96)00093-8

M3 - Article

C2 - 8649205

AN - SCOPUS:0029689910

VL - 58

SP - 2185

EP - 2199

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 24

ER -